Market Research Report
Sleep Disorders Drug Development Pipeline Review, 2017
|Published by||GlobalData||Product code||564941|
|Published||Content info||76 Pages
Delivery time: 1-2 business days
|Sleep Disorders Drug Development Pipeline Review, 2017|
|Published: September 26, 2017||Content info: 76 Pages||
Restless legs syndrome is characterized by a distressing, irresistible need or urge to move the legs. There are a total of eight products in development for this indication, by eight companies. Key companies operating in this pipeline space include Mundipharma International and Galenica.
Nocturia describes the excessive urination at night. There are a total of eight products in development for this indication, by six companies. Key companies operating in this pipeline space include Ferring International and Sanwa Kagaku Kenkyusho.
Finally, Insomnia is a serious sleeping disorder characterized by the inability to fall or stay asleep. There are a total of 31 products in development for this indication, by 27 companies and three academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Merck and Overseas Pharmaceuticals.
Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.
The report,"Sleep Disorders Drug Development Pipeline Review, 2017" provides an overview of the sleep disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia and features dormant and discontinued projects.